PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15564778-0 2004 Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Bleomycin 69-78 interleukin 13 Mus musculus 16-30 15564778-6 2004 RESULTS: RT-PCR showed that both IL-4 and IL-13 mRNA levels in skin lesions were increased and peaked after 4 weeks of bleomycin treatment. Bleomycin 119-128 interleukin 13 Mus musculus 42-47 15564778-10 2004 In skin lesions, IL-13 receptor (IL-13R) alpha2 expression was augmented mainly in the infiltrating mononuclear cells after 4 weeks of bleomycin exposure. Bleomycin 135-144 interleukin 13 Mus musculus 17-22 15564778-13 2004 CONCLUSION: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma. Bleomycin 241-250 interleukin 13 Mus musculus 66-71 15564778-13 2004 CONCLUSION: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma. Bleomycin 241-250 interleukin 13 Mus musculus 155-160 28775096-7 2017 Importantly, in vivo findings demonstrated that IL-13 augments matrix metalloproteinase (MMP)-2 and MMP9 activity that has also been shown to increase migration and invasiveness of fibroblasts in the lungs during bleomycin-induced pulmonary fibrosis. Bleomycin 213-222 interleukin 13 Mus musculus 48-53 12928422-4 2003 IL-4, IL-13, and their corresponding receptor subunits, IL-4Ralpha, IL-13Ralpha1, and IL-13Ralpha2, were maximally expressed at the mRNA and protein levels in whole lung samples on day 21 or 28 after an intratracheal bleomycin challenge. Bleomycin 217-226 interleukin 13 Mus musculus 6-11 31106564-11 2019 Finally, ST2 deficiency diminished the bleomycin-induced B7H3 and IL-13 upregulation, suggesting a role for type 2 innate lymphoid cells (ILC2). Bleomycin 39-48 interleukin 13 Mus musculus 66-71 12928422-5 2003 The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group. Bleomycin 148-157 interleukin 13 Mus musculus 36-41 12928422-5 2003 The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group. Bleomycin 148-157 interleukin 13 Mus musculus 73-77 12928422-5 2003 The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group. Bleomycin 251-260 interleukin 13 Mus musculus 36-41 12928422-5 2003 The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28, but not for 1-wk periods at earlier times, after bleomycin challenge had a significant therapeutic effect on histological and biochemical parameters of bleomycin-induced pulmonary fibrosis compared with the control group. Bleomycin 251-260 interleukin 13 Mus musculus 73-77 12928422-6 2003 The intranasal IL13-PE therapy significantly reduced the numbers of IL-4 and IL-13 receptor-positive mononuclear cells and macrophages and the levels of profibrotic cytokine and chemokine in the lungs of bleomycin-challenged mice on day 28. Bleomycin 204-213 interleukin 13 Mus musculus 15-19 12928422-7 2003 Thus, this study demonstrates that IL-4- and/or IL-13-binding cells are required for the maintenance of pulmonary fibrosis induced by bleomycin and highlights the importance of further investigation of antifibrotic therapeutics that target these cells during pulmonary fibrosis. Bleomycin 134-143 interleukin 13 Mus musculus 48-53 34719405-8 2021 When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group. Bleomycin 78-87 interleukin 13 Mus musculus 133-138 29782549-7 2018 Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes. Bleomycin 0-9 interleukin 13 Mus musculus 85-90 29782549-8 2018 BALF cells from bleomycin-administered wild-type mice showed a marked increase in phosphorylation of STAT6, a transcription factor which is activated downstream of IL-13, compared with saline-administered wild-type mice. Bleomycin 16-25 interleukin 13 Mus musculus 164-169 25551570-9 2014 Instillation of bleomycin but not Ad increased the expression of IL-1alpha, IL-13 and IL-16. Bleomycin 16-25 interleukin 13 Mus musculus 76-81 26153764-0 2016 A protective role for IL-13 receptor alpha 1 in bleomycin-induced pulmonary injury and repair. Bleomycin 48-57 interleukin 13 Mus musculus 22-27 26153764-4 2016 We report dysregulated levels of IL-13 receptors in the lungs of bleomycin-treated mice and to some extent in idiopathic pulmonary fibrosis patients. Bleomycin 65-74 interleukin 13 Mus musculus 33-38 26153764-7 2016 Increased pathology in bleomycin-treated Il13ra1(-/-) mice was due to IL-13Ralpha1 expression in structural and hematopoietic cells but not due to increased responsiveness to IL-17, IL-4, IL-13, increased IL-13Ralpha2 or type 1 IL-4R signaling. Bleomycin 23-32 interleukin 13 Mus musculus 70-75 26519529-3 2015 These pulmonary CD8(+) T cells differentiate into IL-13-producing Tc2 cells and play a major role in a bleomycin-induced model of fibrosis. Bleomycin 103-112 interleukin 13 Mus musculus 50-55 25595781-9 2015 Using an in vitro coculture system, macrophages isolated from in vivo bleomycin-challenged WT, but not IRAK-M(-/-), mice promoted increased collagen and alpha-smooth muscle actin expression from lung fibroblasts in an IL-13-dependent fashion. Bleomycin 70-79 interleukin 13 Mus musculus 218-223 23487425-7 2013 Whereas bleomycin-treated Mmp-8(-/-) and WT mice have similar lung levels of several pro- and antifibrotic mediators (TGF-beta, IL-13, JE, and IFN-gamma), Mmp-8(-/-) mice have higher lung levels of IFN-gamma-inducible protein-10 (IP-10) and MIP-1alpha. Bleomycin 8-17 interleukin 13 Mus musculus 128-133 23413283-9 2013 In TSLPR-deficient mice, bleomycin-induced fibrosis was significantly reduced in parallel with significantly reduced local expression of IL-13. Bleomycin 25-34 interleukin 13 Mus musculus 137-142 20090941-8 2010 Surprisingly, histological analysis showed that a prior P. aeruginosa infection attenuated the development of bleomycin-induced pulmonary fibrosis, which was modestly further attenuated by the intranasal administration of IL13-PE. Bleomycin 110-119 interleukin 13 Mus musculus 222-226 23291432-9 2013 Consistent with these findings, IL-13 levels were reduced in bleomycin-challenged murine skin upon PXR activation. Bleomycin 61-70 interleukin 13 Mus musculus 32-37